Editorial on the Research Topic Lymphocytes in MS and EAE: More Than Just a CD4
+ World
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that affects nearly two million people worldwide. Disease onset can occur at a young age, leaving sufferers with a significantly reduced quality of life. The fact that there is no cure for MS, plus the fact that its animal model experimental autoimmune encephalomyelitis (EAE) is considered a "classic" model of CD4 + T cell-triggered autoimmunity, has led MS pathogenesis to be an area of intense investigation in the past few decades. Numerous lines of evidence indicate that MS is driven by CD4 + T lymphocyte-mediated mechanisms (1) (2) (3) . Polymorphisms in the HLA class II region are by far the strongest genetic link to MS (4) . Moreover, the majority of currently available MS disease-modifying therapies are believed to act by modulating inflammatory CD4 + T cell responses, although in many cases the effects on other immune cell types are under-studied and may be at least as important. Furthermore, while current immunomodulatory drugs are able to reduce the frequency and severity of MS relapses, they are relatively ineffective in progressive forms of the disease (5) . Attempted blockade of CD4 + T cells using anti-CD4-depleting antibody therapy did not produce clinical benefits to patients with MS (6). In contrast, more global immunosuppressive or immunomodulatory approaches reduce the number of relapses and disease progression of MS patients (7) . Furthermore, numerous publications have presented data generated from autopsy material obtained from human patients supporting the notion that other cell types are involved (8) (9) (10) (11) . There is thus an urgent need to expand our view of immune-related pathogenesis in human disease. Despite evidence that lymphocytes such as B cells and CD8
+ T cells play a role, their contributions are much less well studied experimentally compared to those of CD4 + T cells. In this Special Topic, we promote this expanded view of disease pathogenesis by presenting articles that examine the role played by lymphocytes other than CD4 + T cells in MS and its experimental models.
The B cell-depleting reagents rituximab and ocrelizumab have shown success against relapsing/ remitting (12) and even progressive MS (13) . Thus, it is no surprise that this collection features several submissions considering different aspects of potential B cell contributions to CNS autoimmunity. Both Claes et al. and Michel et al. survey what is known about B cells in MS and discuss potential pathogenic mechanisms including antibody production, cytokine secretion, antigen presentation to T cells, and the promotion of disease from within the CNS. Claes et al. additionally present a detailed review of how B cell subpopulations and effector functions are altered both by broadly specific disease-modifying therapies such as interferon-beta and glatiramer acetate as well as by rituximab and ocrelizumab. B cell infiltration into the CNS in MS was a particular focus of the Michel et al. review, and this was further expanded upon by two additional reviews in this special topic. Blauth et al. describe the signals that may permit B cell entry to the CNS, such as CXCL13, VLA-4, and ICAM. Additionally, they discuss recent evidence suggesting that B cells can also exit the CNS so as to undergo additional affinity maturation in peripheral lymphoid tissues, as well as data indicating that the meninges can support differentiation of CNS-specific B cells independently of the periphery. Once in the CNS, B cells have been described to form aggregates in the meninges akin to tertiary lymphoid organ-like structures, and these are the subject of a review from Pikor et al. In particular, they discuss recent evidence suggesting that antigen-experienced T and B cells accumulate in these structures to promote CNS inflammation.
A common theme of these reviews is the uncertainty regarding the neuropathogenic role of B cells in MS. Interestingly, evidence from the two primary research articles in this issue present a challenge to the hypothesis that autoreactive B cell responses are propagated within meningeal aggregates of lymphocytes. It is tempting to speculate that exposure to EBV, which is an environmental factor strongly associated with MS (14), influences disease outcomes by altering B cell activity. Furthermore, the effectiveness of B cell depletion therapy in MS may be due in part to reduced effector T cell function. While the "immune helper" functions of B cells in MS have been intensely investigated, the classic role of B cells as antibody-secreting cells cannot be neglected. Indeed, the presence of oligoclonal IgG bands in CSF has long been a clinical biomarker of MS and is still used as a differential diagnostic tool (15) . Khorooshi et al. detail what is known about antibodymediated pathogenic mechanisms in CNS autoimmunity. They pay particular attention to the role of anti-aquaporin 4 antibodies in neuromyelitis optica-a disease that has only recently been recognized as being independent of MS. They present a scheme in which these antibodies cross a disrupted blood-brain barrier and target astrocytes for complement-mediated destruction in a T cell-independent manner. CD8 + T cells are present in MS tissue at all stages of disease. They can greatly outnumber CD4 + T cells in lesions, perivascular cuffs, and normal-appearing white matter. Furthermore, unlike CD4 + T cells that mostly remain restricted to the perivascular space, CD8
+ T cells infiltrate deep into the CNS parenchymal lesions (16) (17) , it is tempting to speculate that they may provide part of the answer to the question of how the microbiome can influence autoimmune inflammatory diseases such as MS.
The past decades have seen remarkable progress in unraveling the complex and diversified immune mechanisms that contribute to MS pathobiology. Nevertheless, the precise etiology of MS remains elusive. Furthermore, despite an increasing number of immunomodulatory or immunosuppressive therapies altering relapsing-remitting MS, there is a pressing need for effective treatments for progressive disease. The more expanded view of disease pathology presented in this Special Topic may prove to be the key for the next generation of MS therapies.
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